ALX Oncology Holdings Inc logo

ALX Oncology Holdings Inc

NAS:ALXO (USA)   Ordinary Shares
$ 14.23 -1.37 (-8.78%) 10:08 PM EST
At Loss
P/B:
3.74
Market Cap:
$ 713.66M
Enterprise V:
$ 616.83M
Volume:
272.65K
Avg Vol (2M):
534.94K
Volume:
272.65K
At Loss
Avg Vol (2M):
534.94K

Business Description

ALX Oncology Holdings Inc logo
ALX Oncology Holdings Inc
NAICS : 541714 SIC : 2834
ISIN : US00166B1052

Share Class Description:

ALXO: Ordinary Shares
Description
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Name Current Vs Industry Vs History
Cash-To-Debt 10.63
Equity-to-Asset 0.78
Debt-to-Equity 0.09
Debt-to-EBITDA -0.11
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 76.71
9-Day RSI 72.39
14-Day RSI 65.93
6-1 Month Momentum % 63.97
12-1 Month Momentum % 95.67

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.24
Quick Ratio 5.24
Cash Ratio 5.08

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -7.8
Shareholder Yield % -0.88

Financials (Next Earnings Date:2024-05-10 Est.)

ALXO's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:ALXO

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

ALX Oncology Holdings Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -3.74
Beta 0.7
Volatility % 115.65
14-Day RSI 65.93
14-Day ATR ($) 1.102318
20-Day SMA ($) 12.548
12-1 Month Momentum % 95.67
52-Week Range ($) 3.9357 - 17.42
Shares Outstanding (Mil) 50.15

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

ALX Oncology Holdings Inc Filings

Filing Date Document Date Form
No Filing Data

ALX Oncology Holdings Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

ALX Oncology Holdings Inc Frequently Asked Questions

What is ALX Oncology Holdings Inc(ALXO)'s stock price today?
The current price of ALXO is $14.23. The 52 week high of ALXO is $17.42 and 52 week low is $3.94.
When is next earnings date of ALX Oncology Holdings Inc(ALXO)?
The next earnings date of ALX Oncology Holdings Inc(ALXO) is 2024-05-10 Est..
Does ALX Oncology Holdings Inc(ALXO) pay dividends? If so, how much?
ALX Oncology Holdings Inc(ALXO) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1